 |
|
|
||||||||||||||
 |
|
|
Tethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers — biomarkers — that provide a practical tool to address the growing global challenge of chronic metabolic diseases such as diabetes.
By developing new tests that use protein and other bloodborne biomarkers to identify people at high risk for devastating and preventable diseases, we can arm patients and physicians with knowledge they can use to help prevent disease progression. These biomarkers give a snapshot of an individual's current risk, which may be modifiable. Our goal is to provide clinicians with an objective and convenient means to risk-stratify their patients and help them focus appropriate intervention strategies on those most likely to benefit. Our research strategies lead to sets of biomarkers that can be used to quantify the level of an individual's risk.
We approach the market with a unique combination of strengths:
- A research, management and commercialization team with extensive experience in diagnostic innovation
- Alliances with world-class researchers and partners
- A solid financial foundation
The company has become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: Biomarkers. The company believes there is a large unmet need in both the discovery of potentially important biomarkers and the eventual use of them in routine clinical practice for many significant diseases.
Tethys Bioscience has built expertise, created significant intellectual property, and is executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and ValueCreation. Tethys is focused upon introducing products that yield significant savings to the health care system and improve the quality of life for patients.
- Biomarker discovery efforts are focused on applying advanced research tools to identify important biomarkers associated with diseases that affect many people and are very costly to health care systems throughout the world today.
- Clinical validation involves a complex process that results in defining a set of new biomarkers and the application of the resulting test to enhance current clinical practice.
- Value creation encompasses the use of sophisticated health economic analyses to define appropriate performance criteria for new biomarkers and the execution of market development strategies to drive the adoption of new biomarkers in clinical practice.
Nov 20, 2008
Tethys Bioscience Joins National Diabetes Goal
Company joins national move to ensure Americans know their risk of developing Type 2 Diabetes.
Sep 17, 2008
Tethys Bioscience Announces Acquisition of Lipomics Technologies
Addition of metabolite technology uniquely positions company as it expands its line of predictive diagnostic tests
Jul 2, 2008
Tethys unveils advanced-warning test for diabetes by Michael Fitzhugh
Tethys Bioscience Inc. is launching a new test that can identify people at high risk of developing Type 2 diabetes within five years - allowing them to take steps to reduce their risk.
(East Bay Business Times Friday, June 13, 2008)
Jul 2, 2008
A Predictive Tool for Diabetes By Thomas Goetz
Thomas Goetz, deputy editor of Wired magazine, wrote about Tethys and the PreDx Diabetes Risk Test on his personal blog, which tracks trends and technologies in medicine and health.
(Epidemix.org)
Jun 9, 2008
Diabetes test gives 5-year disease-prediction window.
There is an old saying that seems appropriate when describing Tethys Bioscience's PreDx Diabetes Risk Test: Forewarned is forearmed.
(Medical Device Daily)
Jun 7, 2008
Tethys Bioscience Announces Expanded Availability of PreDx™ Diabetes Risk Test
A Powerful New Tool for Early Identification of High Risk Patients
Early Intervention Can Help Prevent Disease Progression